Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
rna interference
san francisco blog main
2
×
san francisco top stories
akcea therapeutics
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
arrowhead pharmaceuticals
barry greene
boehringer ingelheim
boston university
dan ollendorf
deals
dicerna pharmaceuticals
drugs
eli lilly
fda
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
john berk
johnson & johnson
mary o'donnell
neurodegenerative diseases
new york blog main
new york top stories
patisiran
primary hyperoxaluria
regeneron pharmaceuticals
san diego blog main
What
ago
rna
2
×
abandoning
alnylam
approve
awaits
baggage
biological
companies
crossed
cuts
deal
decades
decision
development
dicerna
discovered
fda
fingers
free
friday
gets
historic
interference
long
medicine
medicines
patients
pharma
rnai
signs
small
time
trick
uses
wasn’t
Language
Current search:
rna
×
biotech
×
" san francisco blog main "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision